Literature DB >> 8957020

Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy.

E Pegoraro1, P Mancias, S H Swerdlow, R B Raikow, C Garcia, H Marks, T Crawford, V Carver, B Di Cianno, E P Hoffman.   

Abstract

Ten laminin alpha2-deficient patients were identified by both immunofluorescence and immunoblotting (30% of congenital muscular dystrophy patients tested). Three of the laminin alpha2-deficient patients were carrying a diagnosis of infantile polymyositis prior to immunostaining studies. The clinical features in the 10 merosin-deficient patients were homogeneous, with severe floppiness at birth, delay in achievement of motor milestones, and magnetic resonance imaging findings of white matter changes with normal intelligence. The 10-kb laminin alpha2-coding sequence was screened for causative mutations by reverse transcriptase-polymerase chain reaction/single-stranded conformational polymorphism analysis in muscle biopsy specimens from 5 patients, followed by automatic sequencing of aberrant conformers. Clear loss-of-function deletion mutations were identified in both alleles of 1 patient. Muscle histopathology in this patient showed a striking inflammatory infiltrate of T cells and B cells. Reexamination of biopsy specimens from other laminin alpha2-deficient patients showed minor signs of inflammation in each. Based on these findings and the histological and clinical picture suggesting failure of muscle regeneration, a pathogenesis model for this major subset of congenital muscular dystrophy is proposed. Our data show that muscle histopathology showing a neonatal inflammatory process should be considered consistent with congenital muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957020     DOI: 10.1002/ana.410400515

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

2.  Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.

Authors:  Katherine E Wardrop; Janice A Dominov
Journal:  J Histochem Cytochem       Date:  2011-02       Impact factor: 2.479

Review 3.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 4.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

5.  Merosin-deficient congenital muscular dystrophy with cerebral white matter changes: a clue to its diagnosis beyond infancy.

Authors:  Sandeep Kumar; Shrikiran Aroor; Suneel Mundkur; Maneesh Kumar
Journal:  BMJ Case Rep       Date:  2014-03-06

6.  Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.

Authors:  Jinger A Doe; Ryan D Wuebbles; Erika T Allred; Jachinta E Rooney; Margaret Elorza; Dean J Burkin
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

7.  PCR based mutation screening of the laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy.

Authors:  P Guicheney; N Vignier; X Zhang; Y He; C Cruaud; V Frey; A Helbling-Leclerc; P Richard; B Estournet; L Merlini; H Topaloglu; M Mora; J P Harpey; C A Haenggeli; A Barois; B Hainque; K Schwartz; F M Tomé; M Fardeau; K Tryggvason
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

Review 8.  The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.

Authors:  K J Jones; G Morgan; H Johnston; V Tobias; R A Ouvrier; I Wilkinson; K N North
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

9.  Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.

Authors:  Jachinta E Rooney; Jolie R Knapp; Bradley L Hodges; Ryan D Wuebbles; Dean J Burkin
Journal:  Am J Pathol       Date:  2012-02-06       Impact factor: 4.307

10.  Serological muscle loss biomarkers: an overview of current concepts and future possibilities.

Authors:  Anders Nedergaard; Morten A Karsdal; Shu Sun; Kim Henriksen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-21       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.